Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Albendazole

SKU: orb1224704

Description

Albendazole is a member of the benzimidazole compounds used as a drug indicated for the treatment of a variety of worm infestations.(In Vitro):Albendazole (100, 500, 1000 nM; 1, 3, or 5 days) inhibits cell proliferation in a dose-dependent manner.Albendazole (100, 250, 500, 1000 nM; 3 days) arrests SKHEP-1 cells at both G0–G1 (250, 500 nM) and G2-M (1000 nM) phases of the cycle.Albendazole (5 μM; 24, 36 h) mainly induces early apoptosis in HCT-15 cells and late apoptosis in HCT-1 16, HT29, SW480 cells accompanied with cleavage of PARP and caspase-3 in a time-dependent manner.Albendazole (5 μM; 24, 36 h) induces autophagy via increasing autophagy-related protein (such as LC3, Atg7, p-beclin-1, and beclin-1) expression level in HCT-15, HCT-1 16, HT29, and SW480 cells.Albendazole (500 nM, 24 h) inhibits hypoxia-induced HIF-1α expression and VEGF expression in A549 cells.(In Vivo):Albendazole (10 mg/kg; i.g.; once a day for 30 days) reduces Echinococcus granulosus cyst weights in mice.Albendazole (300 mg/kg; p.o.; per day in two divided dose for 20 days) profoundly suppresses tumor growth in vivo.

Research Area

Pharmacology & Drug Discovery

Images & Validation

Key Properties

CAS Number54965-21-8
MW265.33
Purity>98% (HPLC)
FormulaC12H15N3O2S
SMILESCCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
TargetMicrotubule/Tubulin
SolubilityDMSO: 17mg/ml (64.07 mM); Water: <1mg/ml; Ethanol: <1mg/ml

Bioactivity

In Vivo
Albendazole (10 mg/kg; i. g. ; once a day for 30 days) reduces Echinococcus granulosus cyst weights in mice. Albendazole (300 mg/kg; p.o. ; per day in two divided dose for 20 days) profoundly suppresses tumor growth In vivo. Animal model: Female BALB/c mice (10-week-age; Echinococcus granulosus infection model). Dosage: 10 mg/kg. Administration: Oral gavage; once a day for 30 days. Result: Reduced Echinococcus granulosus cyst weights. Animal model: Male BALB/c Nu/Nu mice (6 to 10-week-old; inoculated subcutaneously with SKHEP-1). Dosage: 50, 150, 300 mg/kg. Administration: Oral administration; per day in two divided dose for 20 days. Result: Profoundly suppressed tumor growth In vivo.
In Vitro
Albendazole (100, 500, 1000 nM; 1, 3, or 5 days) inhibits cell proliferation in a dose-dependent manner. Albendazole (100, 250, 500, 1000 nM; 3 days) arrests SKHEP-1 cells at both G0-G1 (250, 500 nM) and G2-M (1000 nM) phases of the cycle. Albendazole (5 μM; 24, 36 h) mainly induces early apoptosis in HCT-15 cells and late apoptosis in HCT-1 16, HT29, SW480 cells accompanied with cleavage of PARP and caspase-3 in a time-dependent manner. Albendazole (5 μM; 24, 36 h) induces autophagy via increasing autophagy-related protein (such as LC3, Atg7, p-beclin-1, and beclin-1) expression level in HCT-15, HCT-1 16, HT29, and SW480 cells. Albendazole (500 nM, 24 h) inhibits hypoxia-induced HIF-1α expression and VEGF expression in A549 cells. Cell Proliferation Assay. Cell line: SKHEP-1 cells. Concentration: 100, 500, 1000 nM. Incubation time: 1, 3, or 5 days. Result: Inhibited cell proliferation in a dose-dependent manner. Cell Cycle Analysis Cell line: SKHEP-1 HCC cells. Concentration: 100, 250, 500, 1000 nM. Incubation time: 3 days. Result: Showed dose-dependent effect on the cell cycle kinetics. Apoptosis Analysis. Cell line: HCT-15, HCT-1 16, HT29, SW480 cells. Concentration: 5 μM. Incubation time: 24, 36 h. Result: Promoted apoptosis in colon cancer cells. Cell Autophagy Assay Cell line: HCT-15, HCT-1 16, HT29, SW480 cells. Concentration: 5 μM. Incubation time: 24, 36 h. Result: Induced autophagy in colon cancer cells. Western blot analysis. Cell line: HCT-15, HCT-1 16, HT29, SW480 cells. Concentration: 5 μM. Incubation time: 12, 24, 36 h. Result: Induced apoptosis-related protein (PARP, caspase-3) and autophagy-related protein (such as LC3, Atg7, p-beclin-1, and beclin-1) expression level in a time-dependent manner. Increased phosphorylation of different MAPKs (AMPK, ERK, JNK, p38) and ULK1 protein in a time dependent manner, and up-regulated the activation of different MAPKs. Caused the activation of both MAPK and AMPK pathways. Western blot analysis. Cell line: A549 cells. Concentration: 500 nM. Incubation time: 24 h. Result: Inhibited hypoxia-induced HIF-1α expression and VEGF expression in A549 cells.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

NSC 220008 | SKF 62979

Similar Products

  • CYP3A4 Antibody [orb3160062]

    ELISA,  ICC,  IHC,  WB

    Human, Mouse, Rat

    Rabbit

    Polyclonal

    Unconjugated

    50 μl, 100 μl
  • CYP3A4 Antibody [orb3160903]

    ELISA,  ICC,  IHC,  WB

    Human, Mouse, Rat

    Rabbit

    Polyclonal

    Unconjugated

    50 μl, 100 μl
  • CYP3A4 Antibody [orb3161384]

    ELISA,  ICC,  IHC,  WB

    Human, Mouse, Rat

    Rabbit

    Polyclonal

    Unconjugated

    50 μl, 100 μl
  • Human Cytochrome P450 3A4 (CYP3A4) ELISA Kit [orb777811]

    Human

    0.32-20 ng/mL

    0.124 ng/mL

    48 T, 96 T
  • Rat Cytochrome P450 3A4 (CYP3A4) ELISA Kit [orb782155]

    Rat

    0.312-20 ng/mL

    0.127 ng/mL

    48 T, 96 T
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Protocol Information

Available Sizes

Select a size below

50 mg
$ 80.00
100 mg
$ 90.00
200 mg
$ 110.00
500 mg
$ 140.00